Aristotle Atlantic Partners, LLC - SAGE THERAPEUTICS INC ownership

SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 213 filers reported holding SAGE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.1%.

Quarter-by-quarter ownership
Aristotle Atlantic Partners, LLC ownership history of SAGE THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$9,292,375
+41.5%
197,626
+26.3%
0.35%
+3.6%
Q1 2023$6,567,537
+10.3%
156,519
+0.3%
0.34%
+1.5%
Q4 2022$5,953,540
-2.8%
156,097
-0.2%
0.33%
-10.7%
Q3 2022$6,127,000
+22.3%
156,478
+0.9%
0.37%
-3.1%
Q2 2022$5,011,000
-0.5%
155,118
+2.0%
0.38%
+23.4%
Q1 2022$5,035,000
-21.6%
152,103
+0.8%
0.31%
-16.4%
Q4 2021$6,420,000
-10.2%
150,897
-6.4%
0.37%
-21.1%
Q3 2021$7,146,000
-22.0%
161,290
+0.1%
0.47%
-21.7%
Q2 2021$9,158,000
-24.0%
161,205
+0.1%
0.60%
-31.5%
Q1 2021$12,056,000
-13.3%
161,061
+0.2%
0.88%
-17.9%
Q4 2020$13,911,000
+44.7%
160,805
+2.2%
1.07%
+26.8%
Q3 2020$9,613,000
+228.4%
157,270
+123.4%
0.85%
+201.4%
Q2 2020$2,927,000
+86.0%
70,383
+28.4%
0.28%
+17.1%
Q1 2020$1,574,000
-67.8%
54,824
-18.9%
0.24%
-61.5%
Q4 2019$4,881,000
+148.3%
67,613
+382.6%
0.62%
+10.1%
Q3 2019$1,966,000
-22.8%
14,010
+0.8%
0.57%
-23.5%
Q2 2019$2,545,000
+14.7%
13,903
-0.3%
0.74%
+9.8%
Q1 2019$2,219,000
+94.5%
13,949
+17.1%
0.67%
+67.7%
Q4 2018$1,141,000
+18.7%
11,916
+37.0%
0.40%
-31.5%
Q3 2018$961,000
-29.3%
8,7000.0%0.59%
+24.4%
Q2 2018$1,360,0008,7000.47%
Other shareholders
SAGE THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Integral Health Asset Management, LLC 311,000$10,294,0002.68%
Palo Alto Investors LP 851,719$28,192,0002.18%
Boxer Capital, LLC 1,094,000$36,211,0001.86%
DAFNA Capital Management LLC 180,306$5,968,0001.56%
Deep Track Capital, LP 675,000$22,343,0001.43%
Bellevue Group AG 3,052,404$101,034,0001.17%
Ikarian Capital, LLC 249,907$8,272,0001.09%
Ikarian Capital, LLC 250,000$8,275,0001.09%
Artal Group S.A. 750,000$24,825,0001.04%
SECTOR GAMMA AS 118,476$3,922,0000.85%
View complete list of SAGE THERAPEUTICS INC shareholders